Cue Biopharma, Inc. Stock News

Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling study Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling study

BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today reported second quarter 2026 financial results as well as recent business highlights.

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of James M. Ahlers as Chief Financial Officer.

Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases

BOSTON, July 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 1,418,071 shares of common stoc...

Daniel Camardo, former CEO and executive commercial leader with a track record of successful launches joins the board Viola Meehan, former CFO with broad experience in governance, strategic finance and executive leadership joins the board  BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a precision immuno-engineering company focused on developing transformative ther...

BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage therapeutics company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that Shao-Lee Lin, president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 3:10 p.m. EDT in ...

Moves designed to strengthen leadership and financial position, advance portfolio, and leverage expertise in precision immunoengineering Moves designed to strengthen leadership and financial position, advance portfolio, and leverage expertise in precision immunoengineering